The efficacy and safety of arsenic trioxide with or without all-trans retinoic acid for the treatment of acute promyelocytic leukemia: A meta-analysis
| Autor: | Hong Qi, Hao Wang, Zhengxing Rong, Hong-Zhuan Chen, Bai-song Wang, Xiao-yuan Chen |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Adult
Male Oncology Acute promyelocytic leukemia Cancer Research medicine.medical_specialty Adolescent medicine.medical_treatment Tretinoin Pharmacology Arsenicals Young Adult chemistry.chemical_compound Arsenic Trioxide Leukemia Promyelocytic Acute Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Arsenic trioxide Child Adverse effect neoplasms Survival rate Survival analysis Aged Randomized Controlled Trials as Topic Clinical Trials as Topic Chemotherapy business.industry Oxides Hematology Middle Aged medicine.disease Survival Analysis Leukemia Treatment Outcome chemistry Apoptosis Female business Algorithms |
| Zdroj: | Leukemia Research. 35:1170-1177 |
| ISSN: | 0145-2126 |
| DOI: | 10.1016/j.leukres.2011.06.002 |
| Popis: | Arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) could induce apoptosis and differentiation in acute promyelocytic leukemia (APL) cells, respectively, thus the possibility of synergism between them was raised. This meta-analysis assessed the effectiveness and safety of ATO combined with ATRA in the treatment of APL. Compared with ATO alone, induction therapy with ATO/ATRA significantly increased the complete remission (CR) rate (RR: 1.08, 95% CI: 1.00-1.17, P=0.04), shortened the time to achieve CR (WMD: -6.51, 95% CI: -11.32 to -1.70, P=0.008), and improved the molecular remission rate after consolidation therapy (RR: 1.74, 95% CI: 1.14-2.66, P=0.01) and the 1-year disease-free survival rate (RR: 1.22, 95% CI: 1.00-1.50, P=0.05). There were no statistically significant differences between two treatments in terms of early death and main adverse events. These results suggested that ATO/ATRA could synergistically improve the overall outcome of newly diagnosed and relapsed APL patients, supporting the use of ATO/ATRA as an effective treatment for all APL patients previously untreated with ATO. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect